Research programme: janus kinase inhibitors - Aclaris Therapeutics/ Key Organics
Latest Information Update: 28 Apr 2020
At a glance
- Originator Keyorganics
- Developer Aclaris Therapeutics
- Class
- Mechanism of Action Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alopecia